Status:
TERMINATED
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Lead Sponsor:
Thomas M. Lietman
Collaborating Sponsors:
Bill and Melinda Gates Foundation
Pfizer
Conditions:
COVID-19
SARS-CoV-2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-C...
Detailed Description
Identification of a safe, effective treatment for individuals with mild or moderate COVID-19 that prevents disease progression and reduces hospitalization would reduce the burden on the health system....
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days
- Not currently hospitalized
- Willing and able to receive study drug by mail
- Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone
- No known allergy or other contraindication to macrolides
- Age 18 years or older at the time of enrollment
- No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)
- No recent use of hydroxychloroquine within the past 7 days for participants \>55 years of age
- Not currently taking nelfinavir or warfarin (Coumadin)
- Provision of informed consent
- Not currently pregnant
Exclusion
Key Trial Info
Start Date :
May 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT04332107
Start Date
May 22 2020
End Date
March 30 2021
Last Update
March 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143